Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Atherosclerosis Reports
Published in: Current Atherosclerosis Reports 9/2013

01-09-2013 | Clinical Trials and Their Interpretations (J Plutzky, Section Editor)

Hypoglycemia as a Driver of Cardiovascular Risk in Diabetes

Authors: Amir Moheet, Elizabeth R. Seaquist

Published in: Current Atherosclerosis Reports | Issue 9/2013

Login to get access

Abstract

Severe hypoglycemia in patients with diabetes is associated with increased risk of adverse cardiovascular events and death. Recent large randomized clinical trials in individuals with type 2 diabetes have shown that intensive glycemic control may result in increased mortality, and hypoglycemia has been investigated as a possible cause. Acute hypoglycemia is a proarrhythmic, proinflammatory, and prothrombotic state, and several mechanisms have been proposed to explain how hypoglycemia might increase cardiovascular morbidity and mortality. However, data from large clinical trials do not provide strong evidence to establish hypoglycemia as a cause of increased mortality. Severe hypoglycemia is also a marker of frailty and a predictor of adverse outcomes in patients with diabetes. Individualized therapy should be the goal in patients with diabetes to avoid severe hypoglycemia and any related adverse outcomes.
Literature
1.
Riddle MC. Glycemic control and cardiovascular mortality. Curr Opin Endocrinol Diabetes Obes. 2011;18(2):104–9.PubMedCrossRef
2.
Gerstein HC, Miller ME, Byington RP, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358(24):2545–59.PubMedCrossRef
3.
Patel A, MacMahon S, Chalmers J, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358(24):2560–72.PubMedCrossRef
4.
Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009;360(2):129–39.PubMedCrossRef
5.
Finfer S, Blair D, Bellomo R, et al. Intensive versus conventional glucose control in critically ill patients. N Engl J Med. 2009;360(13):1283–97.PubMedCrossRef
6.
Riddle MC. Counterpoint: intensive glucose control and mortality in ACCORD-still looking for clues. Diabetes Care. 2010;33(12):2722–4.PubMedCrossRef
7.
• Gerstein HC, Miller ME, Genuth S, et al. Long-term effects of intensive glucose lowering on cardiovascular outcomes. N Engl J Med. 2011;364(9):818–28. This report describes the 5-year outcomes for mortality and cardiovascular events in participants in the ACCORD trial.PubMedCrossRef
8.
• Bonds DE, Miller ME, Bergenstal RM, et al. The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study. Br Med J. 2010;340:b4909. Post hoc analysis of the ACCORD study suggests that severe hypoglycemia was likely not the cause of the difference in mortality between the intensive treatment and control arms.CrossRef
9.
• Seaquist ER, Miller ME, Bonds DE, et al. The impact of frequent and unrecognized hypoglycemia on mortality in the ACCORD study. Diabetes Care. 2012;35(2):409–14. This post hoc analysis of the ACCORD study showed that subjects in the intensive control group who experienced more episodes of hypoglycemia had a lower risk of death. One explanation for this interesting finding is that individuals with diabetes who are exposed to frequent hypoglycemia can develop a blunted counterregulatory response to hypoglycemia which could reduce impact of hypoglycemia on cardiovascular function.PubMedCrossRef
10.•
Zoungas S, Patel A, Chalmers J, et al. Severe hypoglycemia and risks of vascular events and death. N Engl J Med. 2010;363(15):1410–8. This retrospective analysis of the ADVANCE study showed severe hypoglycemia was associated with increased risks of cardiovascular events and death.PubMedCrossRef
11.
Skyler JS, Bergenstal R, Bonow RO, et al. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association (vol 32, pg 187, 2009). Diabetes Care. 2009;32(4):754.
12.
Johnston SS, Conner C, Aagren M, et al. Evidence linking hypoglycemic events to an increased risk of acute cardiovascular events in patients with type 2 diabetes. Diabetes Care. 2011;34(5):1164–70.PubMedCrossRef
13.
McCoy RG, Van Houten HK, Ziegenfuss JY, et al. Increased mortality of patients with diabetes reporting severe hypoglycemia. Diabetes Care. 2012;35(9):1897–901.PubMedCrossRef
14.
Hsu P, Sung S, Cheng H, et al. Association of clinical symptomatic hypoglycemia with cardiovascular events and total mortality in type 2 diabetes: a nationwide population-based study. Diabetes Care. 2013;36(4):894–900.PubMedCrossRef
15.
Zhao Y, Campbell CR, Fonseca V, Shi L. Impact of hypoglycemia associated with antihyperglycemic medications on vascular risks in veterans with type 2 diabetes. Diabetes Care. 2012;35(5):1126–32.PubMedCrossRef
16.
Gruden G, Barutta F, Chaturvedi N, et al. Severe hypoglycemia and cardiovascular disease incidence in type 1 diabetes the EURODIAB prospective complications study. Diabetes Care. 2012;35(7):1598–604.PubMedCrossRef
17.
Van den Berghe G, Wouters P, Weekers F, et al. Intensive insulin therapy in critically ill patients. N Engl J Med. 2001;345(19):1359–67.PubMedCrossRef
18.
Van den Berghe G, Wilmer A, Hermans G, et al. Intensive insulin therapy in the medical ICU. N Engl J Med. 2006;354(5):449–61.PubMedCrossRef
19.
Soylemez Wiener R, Wiener DC, Larson RJ. Benefits and risks of tight glucose control in critically ill adults—a meta-analysis. JAMA. 2008;300(8):933–44.CrossRef
20.
Svensson A, McGuire D, Abrahamsson P, Dellborg M. Association between hyper- and hypoglycaemia and 2 year all-cause mortality risk in diabetic patients with acute coronary events. Eur Heart J. 2005;26(13):1255–61.PubMedCrossRef
21.
Kagansky N, Levy S, Rimon E, et al. Hypoglycemia as a predictor of mortality in hospitalized elderly patients. Arch Intern Med. 2003;163(15):1825–9.PubMedCrossRef
22.
Boucai L, Southern WN, Zonszein J. Hypoglycemia-associated mortality is not drug-associated but linked to comorbidities. Am J Med. 2011;124(11):1028–35.PubMedCrossRef
23.
Landstedt-Hallin L, Englund A, Adamson U, Lins P. Increased QT dispersion during hypoglycaemia in patients with type 2 diabetes mellitus. J Intern Med. 1999;246(3):299–307.PubMedCrossRef
24.
• Frier BM, Schernthaner G, Heller SR. Hypoglycemia and cardiovascular risks. Diabetes Care. 2011;34:S132–7. This is a review article on the effects of hypoglycemia on the cardiovascular system.PubMedCrossRef
25.
Robinson R, Harris N, Ireland R, Lee S, Newman C, Heller S. Mechanisms of abnormal cardiac repolarization during insulin-induced hypoglycemia. Diabetes. 2003;52(6):1469–74.PubMedCrossRef
26.
Desouza C, Salazar H, Cheong B, et al. Association of hypoglycemia and cardiac ischemia—a study based on continuous monitoring. Diabetes Care. 2003;26(5):1485–9.PubMedCrossRef
27.
Gerritsen J, Dekker J, TenVoorde B, et al. Impaired autonomic function is associated with increased mortality, especially in subjects with diabetes, hypertension, or a history of cardiovascular disease—the Hoorn study. Diabetes Care. 2001;24(10):1793–8.PubMedCrossRef
28.
Maser R, Mitchell B, Vinik A, Freeman R. The association between cardiovascular autonomic neuropathy and mortality in individuals with diabetes—a meta-analysis. Diabetes Care. 2003;26(6):1895–901.PubMedCrossRef
29.
Cryer P. Mechanisms of hypoglycemia-associated autonomic failure and its component syndromes in diabetes. Diabetes. 2005;54(12):3592–601.PubMedCrossRef
30.
Davis S, Galassetti P, Wasserman D, Tate D. Effects of antecedent hypoglycemia on subsequent counterregulatory responses to exercise. Diabetes. 2000;49(1):73–81.PubMedCrossRef
31.
Adler GK, Bonyhay I, Fainng H, et al. Antecedent hypoglycemia impairs autonomic cardiovascular function implications for rigorous glycemic control. Diabetes. 2009;58(2):360–6.PubMedCrossRef
32.
Wright RJ, Newby DE, Stirling D, et al. Effects of acute insulin-induced hypoglycemia on indices of inflammation putative mechanism for aggravating vascular disease in diabetes. Diabetes Care. 2010;33(7):1591–7.PubMedCrossRef
33.
Joy NG, Hedrington MS, Briscoe VJ, et al. Effects of acute hypoglycemia on inflammatory and pro-atherothrombotic biomarkers in individuals with type 1 diabetes and healthy individuals. Diabetes Care. 2010;33(7):1529–35.CrossRef
Metadata
Title
Hypoglycemia as a Driver of Cardiovascular Risk in Diabetes
Authors
Amir Moheet
Elizabeth R. Seaquist
Publication date
01-09-2013
Publisher
Springer US
Published in
Current Atherosclerosis Reports / Issue 9/2013
Print ISSN: 1523-3804
Electronic ISSN: 1534-6242
DOI
https://doi.org/10.1007/s11883-013-0351-7

Other articles of this Issue 9/2013

Current Atherosclerosis Reports 9/2013 Go to the issue

Nutrition (BV Howard, Section Editor)

The Role of Dietary Proteins Among Persons with Diabetes

Nutrition (BV Howard, Section Editor)

Calibration of Self-Reported Dietary Measures Using Biomarkers: An Approach to Enhancing Nutritional Epidemiology Reliability

Cardiovascular Disease and Stroke (D Leifer and JE Safdieh, Section Editors)

Review of Stroke Center Effectiveness and Other Get with the Guidelines Data

Clinical Trials and Their Interpretations (J Plutzky, Section Editor)

Nuclear Reprogramming and Its Role in Vascular Smooth Muscle Cells

Clinical Trials and Their Interpretations (J Plutzky, Section Editor)

Atherosclerosis and Transit of HDL Through the Lymphatic Vasculature

Nutrition (BV Howard, Section Editor)

Recent Economic Evaluations of Interventions to Prevent Cardiovascular Disease by Reducing Sodium Intake
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits